valine has been researched along with Apoplexy in 43 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 23 (53.49) | 29.6817 |
| 2010's | 19 (44.19) | 24.3611 |
| 2020's | 1 (2.33) | 2.80 |
| Authors | Studies |
|---|---|
| Geng, G; Li, Y; Liu, L; Wang, L; Wang, X; Wang, Z; Xu, H; Xu, X; Zhang, Y | 1 |
| de Boer, RGA; Heijenbrok-Kal, MH; Ribbers, GM; Spielmann, K; van de Sandt-Koenderman, WME; van der Vliet, R | 1 |
| Deng, X; Ding, D; Leng, H; Pan, L; Xu, Y | 1 |
| French, MA; Morton, SM; Pohlig, RT; Reisman, DS | 1 |
| Califf, RM; Chiang, FT; Giles, TD; Haffner, SM; Holman, RR; Mazzone, T; McMurray, JJ; Preiss, D; Rutten, GE; Standl, E; Sun, JL; Thomas, LE; Tognoni, G | 1 |
| Kondo, T; Maeda, K; Matsushita, K; Muramatsu, T; Murohara, T; Nagahiro, T; Shintani, S; Yamashita, K | 1 |
| Califf, RM; Kober, L; Lewis, EF; Li, Y; Pfeffer, MA; Reed, SD; Rouleau, JL; Schulman, KA; Solomon, SD; Velazquez, EJ; Weinfurt, KP; White, HD | 1 |
| Asgari Mobarake, K; Keshavarz, P; Leili, EK; Rezaei, S; Saberi, A | 1 |
| Dong, YF; Fukuda, M; Kataoka, K; Kim-Mitsuyama, S; Matsuba, S; Nakamura, T; Ogawa, H; Tamamaki, N; Tokutomi, Y; Yamamoto, E | 1 |
| Bethel, MA; Califf, RM; Haffner, SM; Holman, R; Hua, TA; Huntsman-Labed, A; McMurray, J | 1 |
| Hashimoto, S; Terashi, H; Uchiyama, S | 1 |
| Divchev, D; Grothusen, A; Luchtefeld, M; Schieffer, B | 1 |
| Hall, AS; Strauss, MH | 1 |
| Eto, T; Imai, Y; Imaizumi, T; Ito, S; Kikuchi, K; Kimura, G; Matsuoka, H; Ogihara, T; Rakugi, H; Saruta, T; Shimada, K; Shimamoto, K; Takishita, S; Ueshima, H | 1 |
| Baum, L; Chan, YY; Fu, YP; Hui, CF; Lam, W; Leung, WH; Man, BL; Wong, KS | 1 |
| Hasegawa, H; Kobayashi, Y; Komuro, I; Kuwabara, Y; Mizuma, H; Narumi, H; Shindo, S; Takano, H | 1 |
| Kimura, S; Matsubara, H; Sawada, T; Shiraishi, J; Yamada, H | 1 |
| Cramer, SC; Procaccio, V | 1 |
| Koide, M; Matsubara, H; Sawada, T; Shiraishi, J; Yamada, H | 1 |
| Brunner, HR; Hua, TA; Jia, Y; Julius, S; Kjeldsen, SE; Mancia, G; McInnes, GT; Schork, A; Weber, MA; Zanchetti, A; Zappe, DH | 1 |
| Chujo, M; Hashimoto, T; Ishigaki, M; Kohro, T; Yamazaki, T | 1 |
| Kanorskiĭ, SG; Shevelev, VI | 1 |
| Isaka, N; Ito, M; Kaibuchi, K; Kongo, M; Kureishi, Y; Moriki, N; Nakakuki, T; Nakano, T; Okamoto, R; Seko, T | 1 |
| Williams, B | 1 |
| Banfi, C; Brioschi, M; Crippa, V; de Gasparo, M; Gelosa, P; Gianazza, E; Gianella, A; Guerrini, U; Nobili, E; Sironi, L; Tremoli, E | 1 |
| Aguilar, D; Belenkov, YN; Califf, RM; Diaz, R; Francis, GS; Henis, M; Køber, L; Leimberger, JD; McMurray, JJ; O'Connor, CM; Pfeffer, MA; Rouleau, JL; Skali, H; Solomon, SD; Varshavsky, S; Velazquez, EJ | 1 |
| Bamford, J; Bavington, J; Catto, AJ; Kain, K; Young, J | 1 |
| Califf, R; Howlett, J; Køber, L; Maggioni, A; McMurray, J; Pfeffer, M; Pieper, K; Reed, S; Rouleau, J; Solomon, S; Swedberg, K; Van de Werf, F; Velazquez, E; White, H | 1 |
| Chrysant, GS; Chrysant, SG | 1 |
| Alvarez-Sabín, J; Corral, J; Fernández-Cadenas, I; González-Conejero, R; Iniesta, JA; Marti-Fabregas, J; Montaner, J; Obach, V; Vicente, V | 1 |
| Ebrahimian, T; Gratton, JP; He, Y; Savoia, C; Schiffrin, EL; Touyz, RM | 1 |
| Victor, RG | 1 |
| Califf, RM; Howlett, J; Kober, L; Maggioni, AP; McMurray, JJ; Pfeffer, MA; Rouleau, JL; Signorovitch, J; Solomon, SD; Thune, JJ; Velazquez, EJ; Zelenkofske, S | 1 |
| Achard, JM; Boutitie, F; Fournier, A; Gueyffier, F; Temmar, M | 1 |
| Rupp, H | 1 |
| Amiri, F; Brassard, P; Iglarz, M; Javeshghani, DM; Pu, Q; Schiffrin, EL; Webb, RL | 1 |
| Asai, S; Ishikawa, K; Nishida, Y; Sugahara-Kobayashi, M; Takahashi, Y | 1 |
| Laverty, R; Ledingham, JM | 1 |
| Arriero, MM; Cabestrero, F; Casado, S; de Miguel, LS; Farré, J; García, R; García-Colis, E; Gómez, J; Jiménez, AM; López-Farré, A; Montón, M; Núñez, A; Rico, L | 1 |
7 review(s) available for valine and Apoplexy
| Article | Year |
|---|---|
Determining the most appropriate components for a composite clinical trial outcome.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Diseases; Clinical Trials as Topic; Data Collection; Endpoint Determination; Humans; Myocardial Infarction; Odds Ratio; Outcome Assessment, Health Care; Research Design; Stroke; Tetrazoles; Valine; Valsartan | 2008 |
[Beta2-glycoprotein I polymorphism].
Topics: Adult; Alleles; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; beta 2-Glycoprotein I; beta-Thromboglobulin; Female; Genotype; Humans; Leucine; Male; Middle Aged; Platelet Factor 4; Polymorphism, Genetic; Risk Factors; Stroke; Valine | 2008 |
Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Blockers; Cardiovascular Diseases; Consensus; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Follow-Up Studies; Heart Failure; Hospitalization; Humans; Hypertension; Hypertrophy, Left Ventricular; Middle Aged; Practice Guidelines as Topic; Primary Prevention; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Risk Factors; Saralasin; Secondary Prevention; Stroke; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan | 2009 |
VALUE and supremacy of blood pressure control for cardiovascular protection.
Topics: Antihypertensive Agents; Humans; Hypertension; Myocardial Infarction; Stroke; Tetrazoles; Valine; Valsartan | 2004 |
The pleiotropic effects of angiotensin receptor blockers.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Atrial Fibrillation; Diabetes Mellitus; Heart; Humans; Kidney; Losartan; Platelet Aggregation; Stroke; Tetrazoles; Uric Acid; Valine; Valsartan | 2006 |
Pathophysiology of target-organ disease: does angiotensin II remain the key?
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Calcium Channel Blockers; Cardiovascular Diseases; Disease Progression; Humans; Hypertension; Losartan; Myocardial Infarction; Renin; Renin-Angiotensin System; Stroke; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2007 |
Risk reduction by preventing stroke: need for blockade of angiotensin II and catecholamines?
Topics: Acrylates; Angiotensin II Type 1 Receptor Blockers; Catecholamines; Humans; Hypertension; Imidazoles; Norepinephrine; Stroke; Tetrazoles; Thiophenes; Valine; Valsartan | 2007 |
8 trial(s) available for valine and Apoplexy
| Article | Year |
|---|---|
Effects of valsartan versus amlodipine in diabetic hypertensive patients with or without previous cardiovascular disease.
Topics: Aged; Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Case-Control Studies; Death, Sudden, Cardiac; Diabetes Mellitus, Type 2; Female; Heart Failure; Hospitalization; Humans; Hypertension; Male; Middle Aged; Myocardial Infarction; Myocardial Reperfusion; Proportional Hazards Models; Stroke; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2013 |
Impact of cardiovascular events on change in quality of life and utilities in patients after myocardial infarction: a VALIANT study (valsartan in acute myocardial infarction).
Topics: Acute Disease; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Bundle-Branch Block; Captopril; Death, Sudden, Cardiac; Drug Therapy, Combination; Female; Health Status; Heart Failure; Hospitalization; Humans; Male; Myocardial Infarction; Quality of Life; Recurrence; Stroke; Survivors; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2014 |
Determining the most appropriate components for a composite clinical trial outcome.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Diseases; Clinical Trials as Topic; Data Collection; Endpoint Determination; Humans; Myocardial Infarction; Odds Ratio; Outcome Assessment, Health Care; Research Design; Stroke; Tetrazoles; Valine; Valsartan | 2008 |
Target blood pressure for treatment of isolated systolic hypertension in the elderly: valsartan in elderly isolated systolic hypertension study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Heart Rate; Humans; Hypertension; Male; Medical History Taking; Patient Selection; Proportional Hazards Models; Reference Values; Stroke; Systole; Tetrazoles; Valine; Valsartan | 2010 |
Effects of valsartan and amlodipine on home blood pressure and cardiovascular events in Japanese hypertensive patients: a subanalysis of the VART.
Topics: Aged; Albuminuria; Amlodipine; Angina Pectoris; Antihypertensive Agents; Asian People; Blood Pressure; Cardiovascular Diseases; Cause of Death; Creatinine; Death, Sudden; Female; Heart Failure; Humans; Hypertension; Hypertrophy, Left Ventricular; Kidney Failure, Chronic; Male; Middle Aged; Myocardial Infarction; Stroke; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2012 |
Combination effect of calcium channel blocker and valsartan on cardiovascular event prevention in patients with high-risk hypertension: ancillary results of the KYOTO HEART Study.
Topics: Aged; Angina Pectoris; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cardiovascular Diseases; Female; Heart Failure; Humans; Hypertension; Japan; Male; Middle Aged; Myocardial Infarction; Risk Factors; Stroke; Tetrazoles; Valine; Valsartan | 2012 |
Cardio-cerebrovascular protective effects of valsartan in high-risk hypertensive patients with coronary artery disease (from the Kyoto Heart Study).
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Coronary Artery Disease; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypertension; Incidence; Japan; Male; Prospective Studies; Risk Factors; Stroke; Survival Rate; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan | 2012 |
Cardiovascular outcomes in hypertensive patients: comparing single-agent therapy with combination therapy.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Prognosis; Retrospective Studies; Stroke; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2012 |
29 other study(ies) available for valine and Apoplexy
| Article | Year |
|---|---|
Association of Circulating Branched-Chain Amino Acids with Cardiovascular Diseases: A Mendelian Randomization Study.
Topics: Amino Acids, Branched-Chain; Cardiovascular Diseases; Cerebral Hemorrhage; Cohort Studies; Genome-Wide Association Study; Humans; Isoleucine; Leucine; Mendelian Randomization Analysis; Peripheral Arterial Disease; Polymorphism, Single Nucleotide; Stroke; Valine | 2023 |
The Role of the BDNF Val66Met Polymorphism in Recovery of Aphasia After Stroke.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aphasia; Brain-Derived Neurotrophic Factor; Female; Follow-Up Studies; Genotype; Humans; Language Tests; Male; Methionine; Middle Aged; Polymorphism, Single Nucleotide; Recovery of Function; Retrospective Studies; Saliva; Stroke; Stroke Rehabilitation; Valine; Young Adult | 2017 |
Recurrent stroke-like episodes of Wilson disease with a novel Val176fs mutation.
Topics: Adolescent; Copper-Transporting ATPases; Hepatolenticular Degeneration; Humans; Magnetic Resonance Imaging; Male; Mutation; Stroke; Valine | 2018 |
The relationship between BDNF Val66Met polymorphism and functional mobility in chronic stroke survivors.
Topics: Adult; Aged; Aged, 80 and over; Brain-Derived Neurotrophic Factor; Female; Genotype; Humans; Male; Methionine; Middle Aged; Polymorphism, Single Nucleotide; Regression Analysis; Severity of Illness Index; Stroke; Survivors; Valine | 2018 |
Predictors of stroke in patients with impaired glucose tolerance: results from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial.
Topics: Aged; Antihypertensive Agents; Comorbidity; Controlled Clinical Trials as Topic; Cyclohexanes; Drug Therapy, Combination; Female; Glucose Intolerance; Humans; Hypoglycemic Agents; Male; Middle Aged; Nateglinide; Outcome Assessment, Health Care; Phenylalanine; Predictive Value of Tests; Risk Factors; Stroke; Tetrazoles; Valine; Valsartan | 2013 |
Clinical trial rigging: again!
Topics: Angina Pectoris; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Humans; Hypertension; Retraction of Publication as Topic; Scientific Misconduct; Stroke; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2014 |
Brain-derived neurotrophic factor (BDNF) Val66Met polymorphism and post-stroke dementia: a hospital-based study from northern Iran.
Topics: Aged; Aged, 80 and over; Brain-Derived Neurotrophic Factor; Chi-Square Distribution; Dementia; DNA Mutational Analysis; Female; Genotype; Hospitals; Humans; Iran; Male; Methionine; Middle Aged; Polymorphism, Single Nucleotide; Proportional Hazards Models; Risk Factors; Severity of Illness Index; Stroke; Valine | 2016 |
Excess salt causes cerebral neuronal apoptosis and inflammation in stroke-prone hypertensive rats through angiotensin II-induced NADPH oxidase activation.
Topics: Acetophenones; Angiotensin II; Animals; Antihypertensive Agents; Apoptosis; Astrocytes; Blood Pressure; Cerebral Cortex; Enzyme Activation; Enzyme Inhibitors; Humans; Hydralazine; Hypertension; Inflammation; Male; NADPH Oxidases; Neurons; Rats; Rats, Inbred SHR; Reactive Oxygen Species; Sodium Chloride; Stroke; Tetrazoles; Valine; Valsartan | 2008 |
Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study.
Topics: Antihypertensive Agents; Clinical Trials as Topic; Humans; Hypertension; Stroke; Tetrazoles; Valine; Valsartan | 2010 |
Genetic polymorphisms of Chinese patients with ischemic stroke and concurrent stenoses of extracranial and intracranial vessels.
Topics: Aged; Aged, 80 and over; Aryldialkylphosphatase; Asian People; Constriction, Pathologic; Female; Genetic Testing; Glutamate-Cysteine Ligase; Homocysteine; Humans; Lipid Metabolism; Lipoproteins, LDL; Magnetic Resonance Angiography; Magnetic Resonance Imaging; Male; Methylenetetrahydrofolate Reductase (NADPH2); Polymorphism, Genetic; Stroke; Ultrasonography, Doppler, Duplex; Valine | 2010 |
[Antihypertensive therapy in routine practice: fixed or free combination? Fixed combination scores with better prognosis].
Topics: Amlodipine; Amlodipine, Valsartan Drug Combination; Antihypertensive Agents; Drug Combinations; Humans; Hydrochlorothiazide; Hypertension; Medication Adherence; Myocardial Infarction; Stroke; Tetrazoles; Valine | 2011 |
Correlation between genetic polymorphisms and stroke recovery: analysis of the GAIN Americas and GAIN International Studies.
Topics: Aged; Aged, 80 and over; Americas; Apolipoprotein E4; Brain-Derived Neurotrophic Factor; DNA Mutational Analysis; DNA, Mitochondrial; Female; Follow-Up Studies; Genetic Testing; Genotype; Humans; Male; Methionine; Middle Aged; Multivariate Analysis; Outcome Assessment, Health Care; Polymorphism, Genetic; Recovery of Function; Stroke; Valine | 2012 |
The occurrence rate of cerebrovascular and cardiac events in patients receiving antihypertensive therapy from the post-marketing surveillance data for valsartan in Japan (J-VALID).
Topics: Aged; Angina Pectoris; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cerebral Hemorrhage; Cerebral Infarction; Cerebrovascular Disorders; Female; Health Surveys; Heart Failure; Humans; Hypertension; Incidence; Japan; Male; Middle Aged; Myocardial Infarction; Product Surveillance, Postmarketing; Prospective Studies; Registries; Retrospective Studies; Stroke; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2013 |
[Antihypertensive therapy and dynamics of vascular wall rigidity in elderly patients with non-valvular atrial fibrillation].
Topics: Aged; Ankle Brachial Index; Anticholesteremic Agents; Antihypertensive Agents; Arterial Pressure; Arteries; Atrial Fibrillation; Combined Modality Therapy; Drug Monitoring; Female; Fluorobenzenes; Humans; Hypertension; Male; Myocardial Infarction; Perindopril; Pulse Wave Analysis; Pyrimidines; Rosuvastatin Calcium; Stroke; Sulfonamides; Tetrazoles; Treatment Outcome; Ultrasonography, Doppler, Duplex; Valine; Valsartan; Vascular Resistance | 2012 |
[Fixed combination of AT1 blocker and diuretic. Stroke preventive combination for hypertension].
Topics: Drug Combinations; Humans; Hydrochlorothiazide; Hypertension; Stroke; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2002 |
[AT-1 blockers are different in their effects. The forgetful patients begin to notice it especially].
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Diuretics; Double-Blind Method; Drug Combinations; Humans; Hydrochlorothiazide; Hypertension; Losartan; Meta-Analysis as Topic; Placebos; Randomized Controlled Trials as Topic; Sodium Chloride Symporter Inhibitors; Stroke; Tetrazoles; Time Factors; Valine; Valsartan | 2003 |
RhoA activation in vascular smooth muscle cells from stroke-prone spontaneously hypertensive rats.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Aorta; Cells, Cultured; Cyclic AMP; Cyclic GMP; Hypertension; Muscle, Smooth, Vascular; Prazosin; Rats; Rats, Inbred SHR; Rats, Inbred WKY; rho GTP-Binding Proteins; rhoA GTP-Binding Protein; Signal Transduction; Stroke; Tetrazoles; Valine; Valsartan | 2004 |
Anti-inflammatory effects of AT1 receptor blockade provide end-organ protection in stroke-prone rats independently from blood pressure fall.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Anti-Inflammatory Agents; Blood Pressure; Body Weight; Brain; Chemokine CCL2; Immunohistochemistry; Interleukin-1; Kidney; Magnetic Resonance Imaging; Male; Proteinuria; Rats; Rats, Inbred SHR; RNA, Messenger; Stroke; Survival Analysis; Tetrazoles; Transforming Growth Factor beta; Valine; Valsartan | 2004 |
Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Captopril; Cohort Studies; Comorbidity; Diabetes Complications; Diabetes Mellitus; Drug Therapy, Combination; Female; Follow-Up Studies; Heart Failure; Humans; Life Tables; Male; Medical Records; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Proportional Hazards Models; Randomized Controlled Trials as Topic; Risk; Stroke; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left | 2004 |
Factor XIII--circulating levels and Val34Leu polymorphism in relatives of South Asian patients with ischemic stroke.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Asia; Factor XIII; Female; Genotype; Humans; Ischemia; Leucine; Male; Middle Aged; Polymerase Chain Reaction; Polymorphism, Genetic; Stroke; Valine | 2005 |
The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
Topics: Aged; Angina Pectoris; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Atherosclerosis; Captopril; Cardiovascular Diseases; Disease-Free Survival; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Myocardial Infarction; Randomized Controlled Trials as Topic; Recurrence; Stroke; Tetrazoles; Valine; Valsartan | 2006 |
Role of fibrinogen levels and factor XIII V34L polymorphism in thrombolytic therapy in stroke patients.
Topics: Aged; Aged, 80 and over; Brain Ischemia; Cohort Studies; Factor XIII; Female; Fibrinogen; Hemorrhage; Humans; Leucine; Male; Middle Aged; Polymorphism, Genetic; Prospective Studies; Stroke; Thrombolytic Therapy; Treatment Outcome; Valine | 2006 |
Angiotensin II/AT2 receptor-induced vasodilation in stroke-prone spontaneously hypertensive rats involves nitric oxide and cGMP-dependent protein kinase.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Cyclic GMP-Dependent Protein Kinases; Hypertension; Nitric Oxide; Rats; Receptors, Angiotensin; Stroke; Tetrazoles; Valine; Valsartan; Vasodilation | 2006 |
Effect of antecedent hypertension and follow-up blood pressure on outcomes after high-risk myocardial infarction.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Captopril; Cardiovascular Diseases; Female; Follow-Up Studies; Heart Failure; Humans; Hypertension; Male; Middle Aged; Myocardial Infarction; Prognosis; Risk Factors; Stroke; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2008 |
The JIKEI trial.
Topics: Antihypertensive Agents; Blood Pressure; Humans; Hypertension; Japan; Randomized Controlled Trials as Topic; Stroke; Tetrazoles; Valine; Valsartan | 2007 |
Effects of combined AT1 receptor antagonist/NEP inhibitor on vascular remodeling and cardiac fibrosis in SHRSP.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Pressure; Drug Therapy, Combination; Endomyocardial Fibrosis; Endothelium, Vascular; Hydralazine; Hypertension; Male; Mesenteric Arteries; Neprilysin; Rats; Rats, Inbred SHR; Rats, Wistar; Stroke; Tetrazoles; Tyrosine; Valine; Valsartan | 2008 |
Decreased expression of angiotensin II type 1 and type 2 receptors in the brain after long-term administration of antihypertensive drugs in stroke-prone spontaneously hypertensive rat.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressure; Brain Stem; Calcium Channel Blockers; Cerebral Cortex; Disease Models, Animal; Down-Regulation; Enalapril; Hypertension; Male; Rats; Rats, Inbred SHR; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; RNA, Messenger; Stroke; Tetrazoles; Time Factors; Valine; Valsartan | 2008 |
Basilar artery remodelling in the genetically hypertensive rat: effects of nitric oxide synthase inhibition and treatment with valsartan and enalapril.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Basilar Artery; Blood Pressure; Brain; Enalapril; Enzyme Inhibitors; Hypertension; Muscle, Smooth, Vascular; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Rats; Rats, Inbred SHR; Stroke; Tetrazoles; Valine; Valsartan; Ventricular Function, Left | 2000 |
Inhibition of platelet activation in stroke-prone spontaneously hypertensive rats: comparison of losartan, candesartan, and valsartan.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Platelets; Blood Pressure; Humans; Hypertension; Losartan; P-Selectin; Platelet Activation; Platelet Adhesiveness; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Stroke; Tetrazoles; Thromboxane A2; Valine; Valsartan | 2001 |